| 产品描述: | 一种多激酶抑制剂;A multi kinase inhibitor;AD80,一种多激酶抑制剂,对人源RET (c-RET)、BRAF、S6K和SRC活性较强,但对mTOR的活性比AD57或AD58弱。其对RET (c-RET)的IC50值为4 nM。;AD80, a multi kinase inhibitor, has strong activity on human RET (c-RET), BRAF, S6K and SRC, but weak activity on mTOR than ad57 or ad58. Its IC50 value for RET (c-RET) is 4 nm. |
| 体内研究: |
Oral administration of either AD80 or AD81 results in a notable 70-90% of animals developing to adulthood in Drosophila ptc>dRetMEN2Bmodel, a considerable improvement over the efficacy observed with AD57. AD80 also promotes enhanced tumour growth inhibition and reduces body-weight modulation relative to vandetanib in a mouse xenograft model. AD80 rescues 50% of mice transplanted with PTEN-deficient leukemia cells. |
| 参考文献: |
1. Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.Nature. 2012 Jun 6;486(7401):80-4. 2. Liu H, et al. Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.Cell Rep. 2017 Feb 28;18(9):2088-2095. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.112 ml |
10.561 ml |
21.122 ml |
| 5 mM |
0.422 ml |
2.112 ml |
4.224 ml |
| 10 mM |
0.211 ml |
1.056 ml |
2.112 ml |
| 50 mM |
0.042 ml |
0.211 ml |
0.422 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |